The iMig 2016 scientific committee is working to put together an outstanding programme. For session details, please click on the red arrow next to the session title.

 

ONSITE PROGRAMME >>

ABSTRACT BOOK >>

MondayMay 02, 2016

  • 08:25 - 10:30

    PL01: Plenary Session I: Origins of Mesothelioma

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: Jim teWaterNaude, South Africa, Dean Fennell, United Kingdom, Daniel Sterman, USA
    • PL01.01: Welcome Address - Dean Fennell, University of Leicester, United Kingdom
    • PL01.02: The Global Meso Epidemic - Julian Peto, London School of Hygiene and Tropical Medicine, United Kingdom
    • PL01.03: Chrysotile and Cancer - Julian Peto, London School of Hygiene and Tropical Medicine, United Kingdom & David Egilman, Brown University, USA
    • PL01.04: Pleural Mesothelioma and Asbestos Exposure: A CaseControl Study with Quantitative Risk Assessment (Abstract: 155) - Daniela Ferrante, University of Eastern Piedmont, Italy
    • PL01.05: Mechanisms of Asbestos Carcinogenesis and HMGB1 - Haining Yang, University of Hawaii Cancer Center, USA
    • PL01.06: Long-Fibre Carbon Nanotubes Induce Pleural Mesothelioma via Silencing and/or Loss of Key Tumour Suppressor Genes (Abstract: 273) - Tatyana Chernova, MRC Toxicology Unit, United Kingdom
    • PL01.07: The Genomic Landscape of Mesothelioma - Patrick Tarpey, Wellcome Trust Sanger Institute, United Kingdom
    • PL01.08: How the Genome Affects Outcome - Raphael Bueno, Brigham and Women's Hospital and Harvard Medical School, USA
    • PL01.09: Constitutive YAP Activation Induces Malignant Phenotypes of Immortalized Mesothelial Cells (Abstract: 70) - Yoshitaka Sekido, Aichi Cancer Center Research Institute, Japan
  • 10:30 - 11:15

    Networking Break and Poster Viewing

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 11:15 - 12:45

    PL02: Plenary Session II: Predicting the Outcome

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: Steve Mutsaers, Australia, John Edwards, United Kingdom, Sam Armato, USA
    • PL02.01: "The Bad Macrophage Story" - Lisa Coussens, Oregon Health & Science University, USA
    • PL02.02: Clinico-Pathological Staging - the New IASLC System - Valerie Rusch, Memorial Sloan Kettering Cancer Center, USA
    • PL02.03: Impact of Tumor Thickness on Survival after Accelerated Hemithoracic Radiation Followed by Extrapleural Pneumonectomy (Abstract: 141) - Marc De Perrot, Toronto General Hospital and Princess Margaret Cancer Center, Canada
    • PL02.04: "Bio Staging" - the Future - Kenneth O'Byrne, Queensland University of Technology, Australia
    • PL02.05: Mutation Profiles of Malignant Pleural Mesotheliomas According to Molecular Classification (Abstract: 134) - Lisa Quetel, INSERM U.1162, France
    • PL02.06: Final Q & A
  • 12:45 - 14:15

    Poster Viewing / Exhibition / Networking

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 13:15 - 14:15

    SS02: Lunchtime Session: How Much Cancer Does Chrysotile Cause?

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: Jim teWaterNaude, South Africa, Laurie Kazan-Allen, United Kingdom
    • SS02.01: How Much Cancer Does Chrysotile Cause? - Julian Peto, London School of Hygiene and Tropical Medicine, United Kingdom & David Egilman, Brown University, USA
  • 14:05 - 15:45

    MS01: Mini Symposium 1: MARF International Meso UK Mini Symposium

    Location: Hall 10a, International Convention Centre Birmingham, UK
    Chairs: Mary Hesdorffer, USA, Liz Darlison, United Kingdom, Judy Rafferty, Australia
    • MS01.01: Welcome - Liz Darlison, Mesothelioma UK, United Kingdom & Mary Hesdorffer, Mesothelioma Applied Research Foundation, USA
    • MS01.02: Managing Toxicities & Supporting Patients through Radical Radiotherapy - Anastasia Bykova, University Health Network, Canada
    • MS01.03: Surgical Panel - Melissa Culligan, University of Maryland, USA
    • MS01.04: Programme for Nurses to Improve Communication Skills in the Care of People With Mesothelioma in Japan (Abstract: 45) - Yasuko Nagamatsu, St. Luke's International University, Japan
    • MS01.05: Mesothelioma Patients' and Carers' Concerns about Their Diagnosis, Treatment, and Care (Abstract: 67) - Kate Hill, Leeds Institute of Health Sciences, United Kingdom
    • MS01.06: Asbestos-Related Disease Support Groups: A Survey of Their Organisational Structures and Activities (Abstract: 170) - Helen Clayson, Glasgow Caledonian University, United Kingdom
    • MS01.07: Close - Liz Darlison, Mesothelioma UK, United Kingdom & Mary Hesdorffer, Mesothelioma Applied Research Foundation, USA
  • 14:15 - 15:40

    MS02: Mini Symposium 2: Cell Death Mechanisms

    Location: Hall 10b, International Convention Centre Birmingham, UK
    Chairs: Courtney Broaddus, USA, Marion MacFarlane, United Kingdom
    • MS02.01: Setting the Stage for Cell Death - Courtney Broaddus, University of California San Francisco, USA
    • MS02.02: Signalling Pathways Involved in Upregulation of MCL1 in MM; Metabolic Reprogramming Provides a Novel Approach to Sensitise MM (Abstract: 324) - Xiao-Ming Sun, MRC Toxicology Unit, United Kingdom
    • MS02.03: Monoamine Oxydase A as a Potential New Target to Treat Malignant Pleural Mesothelioma (Abstract: 27) - Christophe Blanquart, University of Nantes, France
    • MS02.04: EGFR Tyrosine Kinase Inhibitors Overcome Resistance to Chemotherapy in Malignant Pleural Mesothelioma (Abstract: 125) - Ludovic Dhont, Interdisciplinary Cluster for Applied Genoproteomics (GIGA) of University of Liège, Belgium
    • MS02.05: Tissue Transglutaminase (TG2): A Potential Novel Target for Human Malignant Pleural Mesothelioma Treatment (Abstract: 42) - Giulia Pinton, University of Piemonte Orientale, Italy
    • MS02.06: Autophagy Inhibition Sensitizes Primary Malignant Mesothelioma to a Dual PI3K/mTOR Inhibitor (Abstract: 205) - Sara Galavotti, MRC Toxicology Unit, United Kingdom
    • MS02.07: Autophagy Correlates with Patient Outcome in Mesothelioma (Abstract: 145) - Carlo Follo, University of California San Francisco, USA
    • MS02.08: What Have We Learned? - Marion Macfarlane, MRC Toxicology Unit / Cancer Research UK Centre, United Kingdom
  • 14:15 - 15:45

    MS03: Mini Symposium 3: Imaging and Endpoint Evaluation

    Location: Hall 6, International Convention Centre Birmingham, UK
    Chairs: Samuel Armato, USA, Anna Nowak, Australia
    • MS03.01: Indocyanine Green and Intraoperative Imaging Detects Residual Disease Following Resection of Malignant Pleural Mesothelioma (Abstract: 93) - Jane Keating, University Of Pennsylvania, USA
    • MS03.02: The Value of Delayed Phase Enhancement for Magnetic Resonance Imaging of Malignant Pleural Mesothelioma (Abstract: 370) - Sharyn Katz, University of Pennsylvania Perelman School of Medicine, USA
    • MS03.03: Optimisation of the Methods for Early Contrast Enhancement (ECE)-Magnetic Resonance Imaging in Patients with Mesothelioma (Abstract: 159) - Selina Tsim, Queen Elizabeth University Hospital, United Kingdom
    • MS03.04: Histogram Analysis of DW-MRI Data during Early Chemotherapy Response Predicts Outcome of Inoperable MPM Patients (Abstract: 362) - Johan Coolen, University Hospitals of Leuven, Belgium
    • MS03.05: Correlation of CT Scan Based Tumor Volume Measurement to Actual Resected Tumor Weight: A New T-Factor? (Abstract: 260) - Isabelle Opitz, University Hospital Zürich, Switzerland
    • MS03.06: Dynamic Contrast-Enhanced CT for the Assessment of Tumor Response in Malignant Pleural Mesothelioma: A Pilot Study (Abstract: 78) - Eyjolfur Gudmundsson, University of Chicago, USA
    • MS03.07: Modified RECIST for Mesothelioma: Lessons Learned and Gaps in Application - Anna Nowak, University of Western Australia, Australia
    • MS03.08: Toward Modified RECIST 1.1 for Mesothelioma: Closing the Gaps and Meeting Present-Day Needs - Sam Armato, University of Chicago, USA
    • MS03.09: Final Q & A
  • 14:15 - 15:45

    MS04: Mini Symposium 4: Cell and Vaccine Based Therapy

    Location: Hall 9, International Convention Centre Birmingham, UK
    Chairs: Bruce Robinson, Australia, Steve Albelda, USA
    • MS04.01: Introduction
    • MS04.02: Experimental Models of Human Malignant Mesothelioma in NOD SCID Mice and Nude Rats for Evaluation of in vivo Virotherapy (Abstract: 114) - Joëlle Nader, UMR 892 INSERM / 6299 CNRS, France
    • MS04.03: Tumour Suppressor microRNAs Regulate PD-L1 Expression in Malignant Pleural Mesothelioma (Abstract: 297) - Marissa Williams, Asbestos Diseases Research Institute, Australia
    • MS04.04: PD-1+ T Cells in Mesothelioma Effusions Induce Tumor PD-L1 Expression Making Them Susceptible to Avelumab Mediated ADCC (Abstract: 66) - Raffit Hassan, National Cancer Institute, USA
    • MS04.05: Harnessing the Immune System-Adjuvant Immunotherapy for Mesothelioma (Abstract: 233) - Jarrod Predina, University of Pennsylvania School of Medicine, USA
    • MS04.06: Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma (Abstract: 248) - A Phase I Trial - Tobias Peikert, Mayo Clinic, USA
    • MS04.07: Nivolumab in Malignant Pleural Mesothelioma (NivoMes): An Interim Analysis (Abstract: 284) - Josine Quispel-Janssen, Netherlands Cancer Institute, Netherlands
    • MS04.08: Immune Responses following Intrapleural Administration of Oncolytic HSV1716 in Patients with Malignant Pleural Mesotheliom (Abstract: 181) - Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom
    • MS04.09: Final Q & A
  • 15:45 - 16:30

    Networking Break and Poster Viewing

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 16:30 - 18:00

    MS05: Mini Symposium 5: Optimum Diagnostic Pathway for Suspected Mesothelioma

    Location: Hall 6, International Convention Centre Birmingham, UK
    Chairs: Takashi Nakano, Japan, Robert Rintoul, United Kingdom
    • MS05.01: MesobanK - Today's Biospecimens for Tomorrow's Medicine (Abstract: 85) - Robert Rintoul, Papworth Hospital NHS Foundation Trust, United Kingdom
    • MS05.02: Haptoglobin Phenotype Is a Risk Factor for Malignant Pleural Mesothelioma (Abstract: 202) - Kevin Lamote, Ghent University Hospital, Belgium
    • MS05.03: HMGB1 and Its Isoform Are Sensitive and Specific Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients (Abstract: 118) - Haining Yang, University of Hawaii Cancer Center, USA
    • MS05.04: Expression of microRNAs in MPM as Tool to Identify Novel Therapeutic Targets and Diagnostic/Prognostic Biomarkers (Abstract: 206) - Chiara De Santi, University of Pisa, Italy
    • MS05.05: The Role of Multidisciplinary Diagnostic/Therapeutic Pathway in the Case-Management of Suspected Pleural Mesothelioma (Abstract: 350) - Cristian Rapicetta, Arcispedale Santa Maria Nuova-IRCCS, Italy
    • MS05.06: Launching the North West Regional Mesothelioma MDT; Defining the Patient Pathway (Abstract: 347) - Lorraine Creech, University Hospital of South Manchester, United Kingdom
    • MS05.07: Final Q & A
  • 16:30 - 18:00

    MS06: Mini Symposium 6: Asbestos Control

    Location: Hall 9, International Convention Centre Birmingham, UK
    Chairs: Jim teWaterNaude, South Africa, Laurie Kazan-Allen, United Kingdom
    • MS06.01: Turkey National Mesothelioma Surveillance Program and Asbestos Control (Abstract: 147) - Muzaffer Metintas, Eskisehir Osmangazi University, Turkey
    • MS06.02: Mesothelioma Mortality At 10-year Follow-up In The Atom 002 Screening Study (Abstract: 394) - Ornella Belvedere, York Hospital, United Kingdom
    • MS06.03: Factors Influencing the Asbestos Bodies among Pleural Mesotheliomas and Lung Cancers Examined for Retained Asbestos Fibres s (Abstract: 199) - Enzo Merler, Venetian Mesothelioma Registry, Italy
    • MS06.04: An Ecological Analysis of Cohorts with Environmental and Occupational Mineral Fiber Exposure (Abstract: 156) - Selma Metintas, Eskisehir Osmangazi University, Turkey
    • MS06.05: The Impact of Geographic and Socioeconomic Factors on Prognosis and Treatment Provision in Malignant Pleural Mesothelioma (Abstract: 69) - Anthony Linton, Asbestos Diseases Research Institute, Australia
    • MS06.06: Risk of Second Primary Cancers after Malignant Mesothelioma and Vice Versa (Abstract: 344) - Tianhui Chen, Zhejiang Academy of Medical Sciences, China
    • MS06.07: Mesothelioma Incidence in Sweden - Why Does It Not Go Down? (Abstract: 304) - Gunnar Hillerdal, Gävle Hospital, Sweden
    • MS06.08: Final Q & A
  • 16:30 - 18:00

    MS07: Mini Symposium 7: BAP1 and Genetics

    Location: Hall 10a, International Convention Centre Birmingham, UK
    Chairs: Michele Carbone, USA, Marc Ladanyi, USA
    • MS07.01: Association of BAP1 Gene Expression with Protein Localization and Survival in Epithelioid MPM (Abstract: 239) - Assunta De Rienzo, Brigham and Women's Hospital and Harvard Medical School, USA
    • MS07.02: Somatic BAP1 and NF2 Mutations in Pleural Malignant Mesothelioma and Their Correlation with Clinical Phenotypes (Abstract: 316) - Spyridon Gennatas, Imperial College London, United Kingdom
    • MS07.03: Families with Multiple Cases of Pleural Malignant Mesothelioma without Inheritance of a BAP1 Predisposing Mutation (Abstract: 71) - Valeria Ascoli, Sapienza University, Italy
    • MS07.04: BAP1 and Mesothelioma (Abstract: 288) - Michele Carbone, University of Hawaii Cancer Center, USA
    • MS07.05: BAP-1 Cancer Syndrome Associated Malignancies Were Not Detected among 558 Danish Patients with Malignant Mesothelioma (Abstract: 58) - Vasiliki Panou, Aalborg University Hospital & Aalborg University, Denmark
    • MS07.06: Final Q & A
  • 16:30 - 18:00

    MS08: Mini Symposium 8: Pathology

    Location: Hall 10b, International Convention Centre Birmingham, UK
    Chairs: Marie-Claude Jaurand, France, Doris Rassl, United Kingdom
    • MS08.01: Immunohistochemical Detection of MTAP or BAP1 Protein Loss for Mesothelioma Diagnosis: Comparison with p16 FISH (Abstract: 160) - Kazuki Nabeshima, Fukuoka University School of Medicine, Japan
    • MS08.02: Utility of BAP1 Immunohistochemistry and FISH in the Differential Diagnosis of Malignant Mesothelioma (Abstract: 97) - Kenzo Hiroshima, Tokyo Women's Medical University, Japan
    • MS08.03: Histological Evaluation of Mesotheliomas (Abstract: 278) - Gregor Vlacic, University Clinic Golnik, Slovenia
    • MS08.04: A Gene Panel to Differentiate Malignant Pleural Mesotheliomas from Benign Pleural Lesions (Abstract: 161) - Rossella Bruno, University of Pisa, Ital
    • MS08.05: Necrosis and Solid Growth Pattern Augment Nuclear Grading in Predicting Survival in Epithelioid Malignant Mesothelioma (Abstract: 242) - Aliya Husain, University of Chicago, USA
    • MS08.06: Peritoneal Mesothelioma: Evaluation on Pathology Reporting (Abstract: 76) - Valeria Ascoli, Sapienza University, Italy
    • MS08.07: The Crucial Clinicopathological Approach in Superficial Mesothelial Proliferations; MESOPATH Experience (Abstract: 286) - Francoise Galateau Salle, Cancer Center Leon Berard, France
    • MS08.08: Multi-Omics Integration for Malignant Pleural Mesothelioma Subtypes Characterization (Abstract: 50) - Yuna Blum, Ligue Nationale Contre Le Cancer, France
    • MS08.09: Final Q & A
  • 18:00 - 19:30

    PP01: Poster Mixer and Poster Discussion Session 1

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: Michael Peake, United Kingdom & Sam Armato, USA & Kevin Blyth, United Kingdom & Marie Claude Jaurand, France & Faheez Mohamed, United Kingdom &, Courtney Broaddus & Marion MacFarlane, United Kingdom, USA

TuesdayMay 03, 2016

  • 08:00 - 08:45

    ISS01: Industry-Supported Symposium

    Location: Hall 9, International Convention Centre Birmingham, UK
  • 09:00 - 10:30

    PL03: Plenary Session III: The Knife or the Needle?

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: Najib Rahman, United Kingdom, David Waller, United Kingdom, Seiki Hasegawa, Japan
    • PL03.01: The Evidence for Surgery - Joseph Friedberg, University of Maryland School of Medicine, USA
    • PL03.02: The Evidence for Chemotherapy - Jan Van Meerbeeck, University Hospital Antwerp, Belgium
    • PL03.03: Debate: What Would You Do First in Early Stage MPM - Surgery or Chemotherapy? - Isabelle Opitz, University Hospital Zürich, Switzerland & David Rice, MD Anderson Cancer Center, USA & Raja Flores, Mount Sinai Health System, USA & Peter Szlosarek, Barts Cancer Institute & St. Bartholomew's Hospital, United Kingdom & Rolf Stahel, University Hospital Zürich, Switzerland & Arnaud Scherpereel, Hospital of the University (CHU) of Lille, France
    • PL03.04: Final Q & A
  • 10:30 - 11:15

    Networking Break and Poster Viewing

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 11:15 - 12:45

    PL04: Plenary Session IV: From Genetics to Therapy

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: Richard Lake, Australia, Kenneth O'Byrne, Australia, Paul Baas, Netherlands
    • PL04.01: Matching Drugs with Genes - Ultan McDermott, Wellcome Trust Sanger Institute, United Kingdom
    • PL04.02: The Therapeutic Link Between BAP1 and EZH2 - Lindsay Lafave, Memorial Sloan Kettering Cancer Center, USA
    • PL04.03: Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of EZH2, in Patients with Non-Hodgkin Lymphoma and Solid Tumors (Abstract: 340) - Peter Ho, Epizyme Inc., USA
    • PL04.04: From Chaotic to Specific Genomic Alterations - Sakari Knuutila, University of Helsinki, Finland
    • PL04.05: Differential Response of Malignant Pleural Mesothelioma Cells to Yap Targeted Therapy According to Molecular Classification (Abstract: 124) - Robin Tranchant, INSERM U.1162, France
    • PL04.06: Novel Synergistic Cell Therapies for the Treatment of Malignant Pleural Mesothelioma (Abstract: 208) - Krishna Kolluri, University College London, United Kingdom
  • 12:45 - 14:15

    Poster Viewing / Exhibition / Networking

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 13:15 - 14:15

    ISS02: Industry-Supported Symposium

    Location: Hall 9, International Convention Centre Birmingham, UK
  • 14:15 - 15:45

    MS09: Mini Symposium 9: Surgery (Technical Aspects)

    Location: Hall 6, International Convention Centre Birmingham, UK
    Chairs: Walter Weder, Switzerland, David Waller, United Kingdom
    • MS09.01: Extended Pleurectomy-Decortication for Pleural Mesothelioma in the Elderly - the Need for an Inclusive yet Selective Approach (Abstract: 265) - Annabel Sharkey, University Hospitals of Leicester, United Kingdom
    • MS09.02: A New Prognostic Score for Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma - An Update (Abstract: 266) - Isabelle Opitz, University Hospital Zürich, Switzerland
    • MS09.03: Group Discussion - Consensus on Patient Selection
    • MS09.04: It's Never Too Late To Operate - An Analysis Of Salvage Surgery For Progressing Malignant Pleural Mesothelioma (Abstract: 267) - Annabel Sharkey, University Hospitals of Leicester, United Kingdom
    • MS09.05: Group Discussion - Consensus on Timing of Surgery
    • MS09.06: Evolution of Surgical Approach in Malignant Pleural Mesothelioma (Abstract: 348) - Seiki Hasegawa, Hyogo College of Medicine, Japan
    • MS09.07: When Is Extrapleural Pneumonectomy Necessary? - Walter Weder, University Hospital Zürich, Switzerland
    • MS09.08: The Role of Pleurectomy/Decortication in the Mesothelioma Risk-Benefit Equation - Raja Flores, Mount Sinai Health System, USA
    • MS09.09: Group Discussion - Technical Points of Importance to Obtain a Macroscopic Complete Resection
  • 14:15 - 15:45

    MS10: Mini Symposium 10: Novel Targets – Entering in the Clinic

    Location: Hall 9, International Convention Centre Birmingham, UK
    Chairs: Hedy Kindler, USA, Sanjay Popat, United Kingdom
    • MS10.01: Phase I Study of Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine in Patients with Metastatic Mesothelioma (Abstract: 212) - Raffit Hassan, National Cancer Institute, USA
    • MS10.02: Phase 1 Dose Expansion Experience of ADI-PEG20, Pemetrexed and Cisplatin in Patients with Malignant Mesothelioma (TRAP Study) (Abstract: 150) - Peter Szlosarek, Barts Cancer Institute, United Kingdom
    • MS10.03: Tremelimumab and Durvalumab Combination for First and Second-Line Treatment of Mesothelioma Patients: The NIBITMESO-1 Study (Abstract: 137) - Luana Calabro', University Hospital of Siena, Italy
    • MS10.04: Phase 2 Neoadjuvant Study of VS-6063, a FAK Inhibitor, in Subjects with Surgically Resectable Malignant Pleural Mesothelioma (Abstract: 162) - Raphael Bueno, Brigham and Women's Hospital and Harvard Medical School, USA
    • MS10.05: Phase I Experience with TargomiRs in Malignant Pleural Mesothelioma (Abstract: 245) - Nico Van Zandwijk, Asbestos Diseases Research Institute, Australia
    • MS10.06: Oncolytic Herpesvirus Therapy for Mesothelioma - a Phase I/IIa Trial of Intrapleural HSV1716 (NCT01721018) (Abstract: 168) - Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom
    • MS10.07: A Phase I Clinical Trial of HVJ-Derived Nanoparticle for Chemotherapy-Resistant Malignant Pleural Mesothelioma (Abstract: 100) - Chunman Lee, Osaka University, Japan
    • MS10.08: Final Q & A
  • 14:15 - 15:45

    MS11: Mini Symposium 11: Critical Signaling Pathway

    Location: Hall 10a, International Convention Centre Birmingham, UK
    Chairs: Yoshitaka Sekido, Japan, Daniel Murphy, United Kingdom, Anne Tsao, USA
    • MS11.01: Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth in vivo by Affecting Stroma (Abstract: 24) - Mayura Meerang, University Hospital Zurich, Switzerland
    • MS11.02: SIRT1 at the Crossroads of AKT1 and ERβ in Malignant Pleural Mesothelioma Cells (Abstract: 92) - Laura Moro, University of Piemonte Orientale, Italy
    • MS11.03: Evaluation of Sensitivity to PI3K/mTOR and FAK Inhibition in Pre-Clinical Models of Malignant Mesothelioma (Abstract: 306) - Ian Powley, MRC Toxicology Unit, United Kingdom
    • MS11.04: Identifying MicroRNAs With Therapeutic Potential in Malignant Pleural Mesothelioma (Abstract: 369) - Glen Reid, Asbestos Diseases Research Institute, Australia
    • MS11.05: MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma via Altered Intracellular Drug Localisation (Abstract: 128) - Hannah Moody, Hull York Medical School, United Kingdom
    • MS11.06: Targeting the Rate-Limiting Step of Protein Synthesis Overcomes Chemoresistance in Malignant Mesothelioma (Abstract: 276) - Stefano Grosso, MRC Toxicology Unit, United Kingdom
    • MS11.07: The Role of Monocyte Chemotactic Protein-1 (MCP-1) in Mesothelioma-Induced Malignant Pleural Effusion Formation (Abstract: 246) - Sally Lansley, Institute for Respiratory Health, Australia
    • MS11.08: Final Q & A
  • 14:15 - 15:45

    MS12: Mini Symposium 12: Treatment Advances in Peritoneal Mesothelioma / Palliative Care for All Mesothelioma

    Location: Hall 10b, International Convention Centre Birmingham, UK
    Chairs: Jeremy Steele, United Kingdom, Helen Clayson, United Kingdom
    • MS12.01: Gender and Menopausal Status: Survival in Peritoneal Mesothelioma (Abstract: 53) - Gleneara Bates, Columbia University Medical Center, USA
    • MS12.02: Simultaneous Care (SimC) in Mesothelioma (MM): A Dedicated Team to Prevent Urgent and Unplanned Hospital Admissions (Abstract: 209) - Federica Grosso, SS. Antonio e Biagio e C. Arrigo, Hospital, Italy
    • MS12.03: Open Discussion Session
    • MS12.04: Final Q & A
  • 15:45 - 16:30

    Networking Break and Poster Viewing

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 16:30 - 18:00

    MS13: Mini Symposium 13: Genomics and Drug Sensitivity

    Location: Hall 10a, International Convention Centre Birmingham, UK
    Chairs: Ultan McDermott, United Kingdom, Marc Ladanyi, USA
    • MS13.01: The MexTAg Collaborative Cross: Identifying the Genetic Basis of Mesothelioma (Abstract: 295) - Scott Fisher, National Centre for Asbestos Related Diseases, Australia
    • MS13.02: Translational Control of MPM: Role of eIf6 and MicroRNAs in Metabolism (Abstract: 359) - Stefania Oliveto, INGM - Fondazione Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Italy
    • MS13.03: BAP1 Knockout by CRISPR-Cas9 Genome Editing in Malignant Pleural Mesothelioma Cell Lines for Isogenic Functional Studies (Abstract: 247) - Julija Hmeljak, Memorial Sloan Kettering Cancer Center, USA
    • MS13.04: BAP1 Expression and Impact on Treatment Outcomes in Malignant Pleural Mesothelioma in a Prospective UK Based Clinical Trial (Abstract: 226) - Neelam Kumar, University College London, United Kingdom
    • MS13.05: Relationship of PD-L1 Expression and Prognosis in Epithelioid Mesothelioma (Abstract: 86) - Tohru Tsujimura, Hyogo College of Medicine, Japan
    • MS13.06: Systems Biology Approaches Towards Developing Personalized Cancer Therapies for Malignant Pleural Mesothelioma (MPM) (Abstract: 379) - Marija Krstic-Demonacos, University of Salford, United Kingdom
    • MS13.07: Final Q & A
  • 16:30 - 18:00

    MS14: Mini Symposium 14: Radiotherapy

    Location: Hall 10b, International Convention Centre Birmingham, UK
    Chairs: Noelle O’Rourke, United Kingdom, Andreas Rimner, USA
    • MS14.01: Examining Signaling Pathway Crosstalk in Mesothelioma PDT and RT Sensitivity Using 2D and Novel 3D Tissue Culture Models (Abstract: 366) - Keith Cengel, University of Pennsylvania, USA
    • MS14.02: SYSTEMS-2:Randomised Phase II Trial of Standard versus Dose Escalated Radiotherapy for Pain in Malignant Pleural Mesothelioma (Abstract: 127) - Miranda Ashton, Beatson West of Scotland Cancer Centre, United Kingdom
    • MS14.03: Overcoming Radiation Resistance of Mesothelioma by Activating Tumour Specific Cell Death (Abstract: 138) - Lesley Gilmour, University of Glasgow, United Kingdom
    • MS14.04: Synergistic Effect of Local Radiation Therapy and Immunotherapy in a Mouse Model of MPM (Abstract: 59) - Luis De La Maza-Borja, University Health Network, Canada
    • MS14.05: The SMART Trial - an RCT of Prophylactic Radiotherapy in Preventing Procedure Tract Metastases in Mesothelioma (Abstract: 103) - Nick Maskell, University of Bristol, United Kingdom
    • MS14.06: Final Q & A
  • 16:30 - 18:00

    MS15: Mini Symposium 15: Multimodality

    Location: Hall 6, International Convention Centre Birmingham, UK
    Chairs: Paul Baas, Netherlands, Raphael Bueno, USA
    • MS15.01: Combined Modality Treatment Using Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Single Centre Experience (Abstract: 328) - Philippe Nafteux, KU Leuven-University of Leuven, Belgium
    • MS15.02: Outcome of Trimodality Therapy including Intracavitary Hydrogen Peroxide Treatment in Malignant Pleural Mesothelioma (Abstract: 283) - Mir Hoda, Medical University of Vienna, Austria
    • MS15.03: Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy for Treatment of Pleural Mesothelioma: A 10-Year Experience (Abstract: 192) - Pietro Bertoglio, U.O. Chirurgia Toracica, Italy
    • MS15.04: Radical Pleurectomy and Hyperthermic Intrathoracic Chemoperfusion for the Treatment of Malignant Pleural Mesothelioma a (Abstract: 346) - Laura Klotz, Center for Thoracic Surgery Munich, Germany
    • MS15.05: Intracavitary Cisplatin-Fibrin Application Following Resection of Mesothelioma (Abstract: 262) - Isabelle Opitz, University Hospital Zürich, Switzerland
    • MS15.06: Pleurectomy / Decortication and Intraoperative Intrapleural Hyperthermic CDDP Perfusion for Malignant Pleural Mesothelioma (Abstract: 183) - Kenichi Okubo, Tokyo Medical and Dental University, Japan
    • MS15.07: HIPEC as a Treatment for Malignant Peritoneal Mesothelioma: Are We There Yet? (Abstract: 213) - Gleneara Bates, Columbia University Medical Center, USA
    • MS15.08: Final Q & A
  • 16:30 - 18:00

    MS16: Mini Symposium 16: Novel Immune Strategies

    Location: Hall 9, International Convention Centre Birmingham, UK
    Chairs: Bruce Robinson, Australia, Joachim Aerts, Netherlands, Dan Sterman, USA
    • MS16.01: Blockade of Protein Kinase a (PKA) Localization Augments Trafficking and Anti-Tumor Efficacy of CAR T Cells (Abstract: 196) - Edmund Moon, University of Pennsylvania, USA
    • MS16.02: Characterising T-Cell Responses against Mutated Mesothelioma Neo-Antigens (Abstract: 207) - Bruce Robinson, University of Western Australia, Australia
    • MS16.03: CSF1R-Blockade Synergizes with Dendritic Cell Immunotherapy in a Mesothelioma Preclinical Model (Abstract: 179) - Floris Dammeijer, Erasmus Medical Center, Netherlands
    • MS16.04: Prostaglandin E2-cAMP-Adenosine Nexus in Mesothelioma; Self Amplifying Immunosuppression? (Abstract: 115) - Zsuzsanna Tabi, Cardiff University, United Kingdom
    • MS16.05: Heterotypic 3D Spheroid Tumour Modeling of Mesothelioma to Determine Immune Resistance (Abstract: 177) - Saly Al-Taei, Cardiff University, United Kingdom
    • MS16.06: Immune Escape Correlates Strongly with an Inflamed Phenotype in Malignant Mesothelioma (Abstract: 393) - Yi-Hung Carol Tan, University of Chicago, USA
    • MS16.07: Exploiting Immune Checkpoint Blockade to Develop Effective Therapy for Malignant Mesothelioma (Abstract: 198) - Scott Fisher, National Centre for Asbestos Related Diseases, Australia
    • MS16.08: Final Q & A
  • 18:00 - 19:30

    PP02: Poster Mixer with Poster Discussions 2

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: David Waller, United Kingdom & Noelle O'Rourke, United Kingdom & Takashi Nakano, Japan & Peter Szlosarek, United Kingdom & Paul Baas, Netherlands & Ian Woolhouse, United Kingdom & Rabab Gaafar, Egypt & Mary Hesdorffer, USA & Robert Rintoul, United Kingdom & Sanjay Popat, United Kingdom &, Gary Middleton, United Kingdom

WednesdayMay 04, 2016

  • 08:00 - 08:45

    ISS03: Industry-Supported Symposium

    Location: Hall 6, International Convention Centre Birmingham, UK
  • 09:00 - 10:30

    PL05: Plenary Session V: What is in the Locker Now?

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: Craig Stevens, USA, Takashi Nakano, Japan, Hedy Lee Kindler, USA
    • PL05.01: Phase II Study on Intensity Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma: Final Results (Abstract: 174) - Andreas Rimner, Memorial Sloan Kettering Cancer Center, USA
    • PL05.02: Pneumonitis Predictors in Intensity Modulated Radiation Treatment of Mesothelioma Patients with Two Lungs (Abstract: 169) - Andrew Jackson, Memorial Sloan Kettering Cancer Center, USA
    • PL05.03: Novel Combinations plus Chemotherapy - Arnaud Scherpereel, Hospital of the University (CHU) of Lille, France
    • PL05.04: State of the Art Approach to Fluid Management - Nick Maskell, University of Bristol, United Kingdom
    • PL05.05: Randomized Phase II Study of Adjuvant WT1 Vaccine for Malignant Pleural Mesothelioma (MPM) After Multimodality Therapy (Abstract: 23) - Marjorie Zauderer, Memorial Sloan Kettering Cancer Center, USA
    • PL05.06: Improved Quality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma (Abstract: 368) - Wickii Vigneswaran, Loyola University Medical Center, USA
    • PL05.07: Final Q & A
  • 10:30 - 11:15

    Networking Break and Poster Viewing

    Location: Hall 3, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 11:15 - 12:45

    PL06: Plenary Session VI: The “Immune War” on Mesothelioma

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: Ken O’Byrne, Australia, Luciano Mutti, United Kingdom, Rabab Gaafar, Egypt
    • PL06.01: Targeting Mesothelin - Raffit Hassan, National Cancer Institute, USA
    • PL06.02: "Programmed to Kill" (Cell-Based Therapy) - Joachim Aerts, Erasmus Medical Center, Netherlands
    • PL06.03: Tartgeting Mutations to Penetrate the Immune Shield - Bruce Robinson, University of Western Australia, Australia
    • PL06.04: "Checking It Out" (Immune Checkpoint Blockade) - Hedy Kindler, University of Chicago, USA
    • PL06.05: The Immune Landscape of Human Mesothelioma to Predict Response to anti-PD1 Therapy (Abstract: 363) - Astero Klabatsa, University of Pennsylvania, USA
    • PL06.06: Maximizing the "Immune Attack" - Anna Nowak, University of Western Australia, Australia
    • PL06.07: Final Q & A
  • 12:45 - 13:15

    Presidential Closing and Invitation to iMig 2018

    Location: Hall 1, International Convention Centre Birmingham, UK
    Chairs: , ,
  • 13:30 - 15:30

    SS03: Young Investigators' Session*

    Location: Hall 9, International Convention Centre Birmingham, UK
    Chairs: Sara Busacca, United Kingdom,

    - For details on the Young Investigators' Session, please click on the PDF of the programme.
    *The Scientific Committee welcomes all Young Investigators with a maximum of 10 years of experience.
    **Visitors should be self-funded.

    Please take the time to complete the session survey by clicking here
    • SS03.01: Career Opportunities: Industry - Nikki Roebuck, Clovis Oncology, United Kingdom
    • SS03.02: Career Opportunities: Clinic & Research - Aaron Mansfield, Mayo Clinic, USA
    • SS03.03: Career Opportunities: Mentoring New Investigators - Marie-Claude Jaurand, INSERM UMR-S 1162, France
    • SS03.04: Open Discussion: New Approaches to Translational Research - Marion MacFarlane, MRC Toxicology Unit / Cancer Research UK Centre, United Kingdom & Annabel Sharkey, University Hospitals of Leicester, United Kingdom
    • SS03.05: Networking for Development of New Collaborations and Visits between Labs**

ThursdayMay 05, 2016

FridayMay 06, 2016